BeOne Medicines (ONC) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The study “A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors” was designed to test an early cancer drug from BeiGene. It aimed to see how safe the drug is, how the body handles it, and whether it shows early tumor control in hard‑to‑treat solid cancers.
The main treatment is BGB-A3055, an experimental cancer drug given by IV. It was tested alone and together with tislelizumab, BeiGene’s approved immune therapy, and in some cases with standard chemotherapy to see if combinations boost anti‑tumor effect.
This was an early-stage interventional trial with no randomization, so everyone knew what they were getting. All patients were placed into single treatment groups mainly to explore safety and find suitable doses, not to prove clear survival benefits.
The study began after initial submission on 26 June 2023, marking BeiGene’s push to expand its solid tumor pipeline. The last update on 11 March 2026 shows the status as terminated, signaling an early stop before the originally planned 36‑month run, and suggests the primary and final completion goals were not reached as first expected.
This termination is likely to weigh on sentiment for BeiGene’s early pipeline, raising questions about this asset’s promise and the broader solid tumor strategy. For investors, it may shift focus toward the company’s later-stage programs and benefits peers with stronger early data in solid tumors, while highlighting ongoing risk in first‑in‑human oncology bets.
The study is now listed as terminated on ClinicalTrials.gov, and further details on the update and status are available on the ClinicalTrials portal.
To learn more about ONC’s potential, visit the BeOne Medicines drug pipeline page.